natgillin/translations-raw huggingface dataset:
The effects of renal or hepatic impairment, gender, age or race on the pharmacokinetics of decitabine have not been formally studied.
Vpliva okvare ledvic oziroma jeter, spola, starosti in rasne pripadnosti na farmakokinetiko decitabina niso formalno proučevali.
The effects of repeat dosing of cyclosporine A (100 – 150 mg twice daily) on the steady-state pharmacokinetics of ambrisentan (5 mg once daily), and the effects of repeat dosing of ambrisentan (5 mg once daily) on the steady-state pharmacokinetics of cyclosporine A (100 – 150 mg twice daily) were studied in healthy volunteers.
Učinke ponavljajočih se odmerkov ciklosporina A (100-150 mg dvakrat na dan) na farmakokinetiko ambrisentana (5 mg enkrat na dan) v stanju dinamičnega ravnovesja in učinke ponavljajočih se odmerkov ambrisentana (5 mg enkrat na dan) na farmakokinetiko ciklosporina A (100-150 mg dvakrat na dan) v stanju dinamičnega ravnovesja so raziskali pri zdravih prostovoljcih.
The effects of Riprazo on warfarin pharmacokinetics have not been evaluated.
Učinkov zdravila Riprazo na farmakokinetične lastnosti varfarina niso ocenjevali.
The effects of Seebri Breezhaler were first tested in experimental models before being studied in humans.
Učinki zdravila Seebri Breezhaler so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The effects of smoking, diet, herbal products and alcohol use on the pharmacokinetics of saxagliptin, dapagliflozin or fixed dose combination tablet have not been studied.
Vplivi kajenja, prehrane, zdravil rastlinskega izvora in alkohola na farmakokinetiko saksagliptina, dapagliflozina ali tablet s fiksno kombinacijo niso bili raziskani.
The effects of Sprimeo on warfarin pharmacokinetics have not been evaluated.
Učinkov zdravila Sprimeo na farmakokinetične lastnosti varfarina niso ocenjevali.
The effects of Stelara in pregnant women are not known.
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
The effects of supra-therapeutic doses of dextromethorphan /quinidine (23 mg /26 mg and 46 mg / 53 mg, for 7 consecutive doses) on QTc prolongation were evaluated in a randomised, placebo- controlled, double-blind, crossover design with an additional open-label positive control (400 mg moxifloxacin) arm in 36 healthy volunteers.
Učinki odmerkov dekstrometorfana/kinidina, ki so bili večji od terapevtskih odmerkov (23 mg/26 mg in 46 mg/53 mg v 7 zaporednih odmerkih), na podaljšanje intervala QTc so bili ocenjeni v randomizirani, s placebom nadzorovani, dvojno slepi, navzkrižni študiji z dodatnim odprtim krakom za pozitivno kontrolo (400 mg moksifloksacina) pri 36 zdravih prostovoljcih.
The effects of taking too much Bemfola are unknown.
Učinki jemanja prevelike količine zdravila Bemfola niso znani.
The effects of Tekturna on warfarin pharmacokinetics have not been evaluated.
Učinkov zdravila Tekturna na farmakokinetične lastnosti varfarina niso ocenjevali.
The effects of tenofovir disoproxil fumarate in treatment-experienced and treatment-naïve HIV-1 infected adults have been demonstrated in trials of 48 weeks and 144 weeks duration, respectively.
Učinkovitost dizoproksiltenofovirijevega fumarata so dokazali pri že zdravljenih in še nezdravljenih odraslih, okuženih s HIV-1, v 48 oziroma 144 tednov trajajočih študijah.
The effects of tenofovir disoproxil fumarate-associated changes in BMD on long-term bone health and future fracture risk are currently unknown (see section 5.1).
Učinki dizoproksiltenofovirijevega fumarata, povezani z MGK, na dolgoročno zdravje kosti in bodoče tveganje za zlom, trenutno niso znani (glejte poglavje 5.1).
The effects of the irbesartan and hydrochlorothiazide combination on fertility have not been evaluated in animal studies, as there is no evidence of adverse effect on fertility in animals or humans with either irbesartan or hydrochlorothiazide when administered alone.
Vpliva kombinirane uporabe irbesartana in hidroklorotiazida na plodnost v študijah na živalih niso ugotavljali, kajti neželenih učinkov na plodnost bodisi irbesartana bodisi hidroklorotiazida pri živalih in ljudeh niso dokazali.
the effects of this medicine are known to be short-term.
Znano je, da so učinki tega zdravila kratkotrajni.
The effects of this medicine on the ability to drive and use machines have not been studied.
Vplivov tega zdravila na sposobnost vožnje in upravljanje s stroji niso preučevali.
The effects of Tovanor Breezhaler were first tested in experimental models before being studied in humans.
Učinki zdravila Tovanor Breezhaler so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The effects of trabectedin on cardiovascular and respiratory function have been investigated in vivo (anesthetised Cynomolgus monkeys).
Učinki trabektedina na kardiovaskularne in dihalne funkcije so bili preiskani in vivo (opice Cynomolgus pod narkozo).
The effects of using too much Ovaleap are unknown.
Učinki jemanja prevelike količine zdravila Ovaleap niso znani.
The effects of various covariates on siltuximab PK were assessed in the analyses.
V analizi so ocenjevali vpliv različnih sospremenljivk na farmakokinetiko siltuksimaba.
The effects of Vectibix in addition to ‘best supportive care’ were compared with those of best supportive care alone.
Učinke zdravila Vectibix skupaj z „najboljšo podporno nego“ so primerjali z učinki najboljše podporne nege same.
The effects of Victrelis were first tested in experimental models before being studied in humans.
Učinki zdravila Victrelis so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The effects of Yellox were first tested in experimental models before being studied in humans.
Učinki zdravila Yellox so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The effects of Yervoy have been looked at in two main studies.
Učinke zdravila Yervoy so proučevali v dveh glavnih študijah.
The effects of YERVOY in pregnant women are not known, but it is possible that the active substance, ipilimumab, could harm an unborn baby.
Učinki zdravila YERVOY pri nosečnici niso znani, vendar pa obstaja možnost, da zdravilna učinkovina ipilimumab škoduje nerojenemu otroku.
The effects of Zaltrap were first tested in experimental models before being studied in humans.
Učinki zdravila Zaltrap so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The effects of Zelboraf were first tested in experimental models before being studied in humans.
Učinki zdravila Zelboraf so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The effects on co-administered medicinal products may thus be underestimated and clinical monitoring of safety may be indicated.
Zato so lahko učinki sočasne uporabe zdravil podcenjeni in je potrebno spremljanje varnosti zdravila.
The effects on co-administered medicinal products may thus be underestimated and clinical monitoring of safety may be indicated.
Zato so lahko učinki sočasne uporabe zdravil podcenjeni in je zaradi varnosti potrebno spremljanje.
The effects on parturition are probably mediated by species- specific mechanisms, involving reduction of oestradiol levels, and are consistent with those observed with other azole antifungal agents.
Učinki na porod se verjetno posredujejo z za živalsko vrsto specifičnimi mehanizmi, ki obsegajo zmanjšanje koncentracije estradiola in se skladajo z mehanizmi, ugotovljenimi pri drugih azolskih antimikotikih.
The effects on the ability to drive and to use machines have not been studied.
Študije vpliva na sposobnost upravljanja vozil in strojev niso bile opravljene.
The effects were studied in one main study, which involved over 21,000 patients for an average of 2.5 years.
Njegove učinke so proučevali v eni glavni študiji z 21 000 bolniki, ki so v njej v povprečju sodelovali 2,5 leta.
The effervescent granules are filled in an amount of 5.6 g in sachets with an inner layer of polyester/LD-polyethylene and an outer layer of aluminium/LD-polyethylene.
Šumeča zrnca so pakirana po 5,6 g v blazinice z notranjo plastjo iz poliestra/LD-polietilena in zunanjo plastjo iz aluminija/LD-polietilena.
The effervescent granules are white with a raspberry flavour and are supplied in a sachet.
Šumeča zrnca so bela, z okusom po malinah in pakirana v blazinicah.
The effervescent granules contain sodium hydrogen carbonate, citric acid, sodium carbonate, saccharin sodium, sodium citrate and raspberry flavour.
Šumeča zrnca vsebujejo natrijev hidrogenkarbonat, citronsko kislino, natrijev karbonat, natrij saharinat, natrijev citrat in aromo maline.
The effervescent granules should be dissolved in approximately 150 ml of cool water.
Šumeča zrnca je treba raztopiti v približno 150 ml hladne vode.
The effervescent granules, supplied in a sachet, are white.
Šumeča zrnca, ki so na voljo v blazinicah, so bela.
The efficacy against severe RV gastro-enteritis requiring hospitalisation was 100% (95% CI: 72.4; 100.0).
Učinkovitost proti hudem RV gastroenteritisu, ki je zahteval sprejem v bolnišnico, je bila 100 % (95 % IZ: 72,4; 100,0).
The efficacy analysis includes 3 subjects with recombinant genotype 2/1 HCV infection.
Analiza učinkovitosti vključuje 3 osebe z okužbo s HCV z rekombinantnim genotipom 2/1.
The efficacy analysis includes 6 subjects with recombinant genotype 2/1 HCV infection.
Analiza učinkovitosti vključuje 6 oseb z okužbo s HCV z rekombinantnim genotipom 2/1.
The efficacy and safety have not been fully established for DVT/PE patients with active cancer.
Učinkovitost in varnost zdravila pri bolnikih z GVT ali PE in aktivnim rakom še nista raziskani.
The efficacy and safety of a variation of the Zevalin therapeutic regimen employing a reduced dose of ibritumomab tiuxetan [90Y] was further defined in a third study enrolling a total of 30 patients who had mild thrombocytopenia (platelet count 100,000 to 149,000 cells/mm3).
Učinkovitost in varnost različice terapevtske sheme z zdravilom Zevalin, pri kateri so uporabljali nižje odmerke ibritumomab tiuksetana [90Y], so nadalje proučevali v tretji študiji, v katero je bilo vključenih skupno 30 bolnikov z blago trombocitopenijo (število trombocitov med 100.000 - 149.000 celic/mm3).
The efficacy and safety of abatacept were assessed in randomised, double-blind, placebo-controlled clinical trials in adult patients with active rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria.
Učinkovitost in varnost abatacepta so vrednotili v randomiziranih, dvojno slepih, s placebom nadzorovanih kliničnih preskušanjih pri odraslih bolnikih z aktivnim revmatoidnim artritisom, diagnosticiranim po kriterijih Ameriškega združenja za revmatologijo (ACR-American College of Rheumatology).
The efficacy and safety of Aclasta 5 mg once a year for 3 consecutive years were demonstrated in post-menopausal women (7,736 women aged 65–89 years) with either: a femoral neck bone mineral density (BMD) with a T-score ≤ –1.5 and at least two mild or one moderate existing vertebral fracture(s); or a femoral neck BMD T-score ≤ –2.5 with or without evidence of existing vertebral fracture(s).
Učinkovitost in varnost zdravila Aclasta 5 mg na leto 3 leta zapored so dokazali pri postmenopavzalnih ženskah (7.736 ženskah, starih 65-89 let), ki so imele: bodisi vrednost T mineralne gostote kosti vratu stegnenice ≤ –1,5, pri tem pa prisotna vsaj dva manjša zloma ali en srednje hud zlom vretenca, ali pa vrednost T mineralne gostote kosti vratu stegnenice ≤ –2,5 z znaki prisotnega enega ali več zlomov vretenc ali brez njih.
The efficacy and safety of agomelatine (25 to 50mg/day) have been established in elderly depressed patients (< 75years).
Učinkovitost in varnost agomelatina (25 do 50 mg/dan) sta bili dokazani pri starejših bolnikih z depresijo ( 75 let).
The efficacy and safety of aliskiren-based therapy were compared to ramipril-based therapy in a 9- month non-inferiority study in 901 elderly patients (≥ 65 years) with essential systolic hypertension.
V 9-mesečni študiji, s katero so želeli dokazati, da aliskiren ni slabši kot ramipril, so pri 901 starejšem bolniku (≥ 65 let) z esencialno sistolično hipertenzijo primerjali učinkovitost in varnost zdravljenja na osnovi aliskirena in zdravljenja na osnovi ramiprila.
The efficacy and safety of aliskiren-based therapy were compared to ramipril-based therapy in a 9- month non-inferiority study in 901 elderly patients (≥65 years) with essential systolic hypertension.
V 9-mesečni študiji, s katero so želeli dokazati, da aliskiren ni slabši kot ramipril, so pri 901 starejšem bolniku (≥65 let) z esencialno sistolično hipertenzijo primerjali učinkovitost in varnost zdravljenja na osnovi aliskirena in zdravljenja na osnovi ramiprila.
The efficacy and safety of Avastin in combination with chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan) in the treatment for patients with persistent, recurrent or metastatic carcinoma of the cervix was evaluated in study GOG-0240, a randomised, four-arm, open label, multi- centre phase III trial.
Učinkovitost in varnost zdravila Avastin v kombinaciji s kemoterapijo (paklitaksel in cisplatin ali paklitaksel in topotekan) za zdravljenje bolnic z rakom materničnega vratu, pri katerih je bila bolezen prisotna tudi po zaključenem primarnem zdravljenju, se je ponovila ali je bila metastatska, so ugotavljali v študiji GOG-0240, randomiziranem, odprtem, multicentričnem preskušanju faze III s štirimi skupinami bolnic.
The efficacy and safety of basiliximab were evaluated in two paediatric studies.
Učinkovitost in varnost baziliksimaba so ocenjevali v dveh pediatričnih študijah.
The efficacy and safety of CHAMPIX (1 mg twice daily) for smoking cessation in subjects with mild-moderate COPD was demonstrated in a randomised double-blind placebo-controlled clinical trial.
Učinkovitost in varnost uporabe zdravila CHAMPIX (1 mg dvakrat na dan) za opustitev kajenja pri osebah z blago do zmerno KOPB so dokazali v randomiziranem, dvojno slepem, s placebom nadzorovanim kliničnem preskušanju.
The efficacy and safety of Cimzia have been assessed in 2 randomised, placebo-controlled, double-blind clinical trials in patients ≥ 18 years of age with active rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria, RA-I (RAPID 1) and RA-II (RAPID 2).
Učinkovitost in varnost zdravila Cimzia so ocenili v 2 dvojno slepih, randomiziranih, s placebom nadzorovanih študijah pri bolnikih, starih ≥ 18 let z aktivnim revmatoidnim artritisom, ki je opredeljen v skladu z merili ACR (American College of Rheumatology), RA-I (RAPID 1) in RA- II (RAPID 2).
The efficacy and safety of Cimzia were assessed in a multicentre, randomised, double-blind, placebo controlled clinical trial (PsA001) in 409 patients ≥ 18 years of age with adult-onset active psoriatic arthritis for at least 6 months as defined by the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria.
Učinkovitost in varnost zdravila Cimzia so ocenili v multicentričnem, randomiziranem, dvojno slepem, s placebom nadzorovanem kliničnem preskušanju (PsA001) pri 409 bolnikih, starejših od 18 let, s pojavom aktivnega psoriatičnega artritisa v zadnjih 6 mesecih, ki je bil določen po kriterijih ocene za psoriatični artritis (CASPAR).
The efficacy and safety of Cimzia were assessed in one multicenter, randomized, double-blind, placebo-controlled trial (AS001) in 325 patients ≥18 years of age with adult-onset active axial spondyloarthritis for at least 3 months as defined by the Assessment of Spondyloarthritis International Society (ASAS) Classification Criteria for axial spondyloarthritis.
Učinkovitost in varnost zdravila Cimzia so ocenili v multicentričnem, randomiziranem, dvojno slepem, s placebom nadzorovanim preskušanjem (AS001) pri 325 bolnikih, starejših od 18 let, s pojavom aktivnega aksialnega spondiloartritisa v zadnjih 3 mesecih, ki je bil določen po kriterijih ocene v spondiloartritičnem mednarodnem združenju (ASAS - Assessment of Spondyloarthritis International Society) za aksialni spondiloartritis.
The efficacy and safety of Clomicalm has not been established in dogs weighing less than 1.25 kg or under six months of age.
Ni podatkov o varnosti in učinkovitosti pri uporabi tega zdravila pri psih, lažjih od 1.25 kg in mlajših od 6 mesecev.
The efficacy and safety of Cosentyx 150 mg and 300 mg were evaluated versus either placebo or etanercept.
Učinkovitost in varnost zdravila Cosentyx v odmerkih 150 mg in 300 mg so vrednotili v primerjavi z bodisi placebom ali etanerceptom.
The efficacy and safety of Cymbalta 30-120 mg once daily in elderly patients with generalised anxiety disorder was similar to that seen in studies of younger adult patients.
Učinkovitost in varnost zdravila Cymbalta 30-120 mg enkrat na dan pri starejših bolnikih z generalizirano anksiozno motnjo sta bili podobni kot v študijah z mlajšimi odraslimi bolniki.
The efficacy and safety of dabrafenib have not been established in patients with wild-type BRAF melanoma therefore dabrafenib should not be used in patients with BRAF wild-type melanoma (see sections 4.4 and 5.1).
Učinkovitost in varnost dabrafeniba nista ugotovljeni pri bolnikih z melanomom z divjim tipom BRAF, zato se dabrafeniba pri takšnih bolnikih ne sme uporabljati (glejte poglavji 4.4 in 5.1).
The efficacy and safety of dabrafenib have not been established in patients with wild-type BRAF melanoma therefore dabrafenib should not be used in patients with wild-type BRAF melanoma (see sections 4.2 and 5.1).
Učinkovitost in varnost dabrafeniba nista ugotovljeni pri bolnikih z melanomom z divjim tipom BRAF, zato se dabrafeniba pri teh bolnikih ne sme uporabljati (glejte poglavji 4.2 in 5.1).
The efficacy and safety of Defitelio in the treatment of severe VOD were studied in a pivotal Phase 3 historical-controlled study (2005-01).
Učinkovitost in varnost zdravila Defitelio pri zdravljenju hude VOB so preučevali v ključni, zgodovinsko nadzorovani študiji 3. faze (2005-1).
The efficacy and safety of duloxetine 30-120 mg once daily in elderly patients with generalised anxiety disorder was similar to that seen in studies of younger adult patients.
Učinkovitost in varnost duloksetina 30- 120 mg enkrat na dan pri starejših bolnikih z generalizirano anksiozno motnjo sta bili podobni kot v študijah z mlajšimi odraslimi bolniki.
The efficacy and safety of Duloxetine Lilly 30-120 mg once daily in elderly patients with generalised anxiety disorder was similar to that seen in studies of younger adult patients.
Učinkovitost in varnost zdravila Duloxetine Lilly 30-120 mg enkrat na dan pri starejših bolnikih z generalizirano anksiozno motnjo sta bili podobni kot v študijah z mlajšimi odraslimi bolniki.
The efficacy and safety of eltrombopag for the treatment of thrombocytopenia in patients with HCV infection were evaluated in two randomised, double-blind, placebo-controlled studies.
Učinkovitost in varnost eltrombopaga za zdravljenje trombocitopenije pri bolnikih z okužbo HCV so ocenjevali v dveh randomiziranih, dvojno slepih, s placebom nadzorovanih študijah.
The efficacy and safety of eltrombopag has not been established in subjects with both moderate to severe renal impairment and hepatic impairment.
Učinkovitost in varnost eltrombopaga pri bolnikih z zmerno in hudo okvaro ledvic in okvaro jeter ni bila ugotovljena.
The efficacy and safety of eluxadoline in IBS-D patients was established in two randomized, multi- center, multi-national, double-blind, placebo-controlled studies (Studies 1 & 2).
Učinkovitost in varnost eluksadolina pri bolnikih z IBS-D sta bili ugotovljeni v dveh randomiziranih, multicentričnih, multinacionalnih, dvojno slepih, s placebom nadzorovanih študijah (študiji 1 in 2).
The efficacy and safety of empagliflozin as add-on to antidiabetic therapy was evaluated in patients with renal impairment in a double-blind, placebo-controlled study for 52 weeks.
Učinkovitost in varnost empagliflozina kot dodatnega zdravljenja pri zdravljenju sladkorne bolezni so ocenili pri bolnikih z ledvično okvaro v dvojno slepi, s placebom nadzorovani 52-tedenski študiji.
The efficacy and safety of empagliflozin as add-on to basal insulin with or without metformin and/or a sulphonylurea was evaluated in a double-blind, placebo-controlled trial of 78 weeks duration.
Učinkovitost in varnost empagliflozina kot dodatnega zdravljenja k bazalnemu insulinu z metforminom ali brez njega in/ali sulfonilsečnino so ocenili v dvojno slepem, s placebom nadzorovanem 78-tedenskem preskušanju.
The efficacy and safety of empagliflozin as add-on to multiple daily insulin with concomitant metformin therapy was evaluated in a double-blind, placebo-controlled trial of 52 weeks duration.
Učinkovitost in varnost empagliflozina kot dodatnega zdravljenja k večkratnim dnevnim odmerkom insulina s sočasnim zdravljenjem z metforminom so ocenili v dvojno slepem, s placebom nadzorovanem 52-tedenskem preskušanju.
The efficacy and safety of empagliflozin as add-on to multiple daily insulin with or without concomitant metformin therapy was evaluated in a double-blind, placebo-controlled trial of 52 weeks duration.
Učinkovitost in varnost empagliflozina kot dodatno zdravljenje k večkratnim dnevnim odmerkom insulina s sočasnim zdravljenjem z metforminom ali brez njega so ocenili v dvojno slepem, s placebom nadzorovanem 52-tedenskem preskušanju.
The efficacy and safety of Envarsus and Prograf, both in combination with Mycophenolate Mofetil (MMF) corticosteroids, and IL-2 receptor antagonist as per the standard of care was compared in a randomised, double-blind, double-dummy study, in 543 de novo kidney transplant recipients.
Učinkovitost in varnost zdravila Envarsus in zdravila Prograf, oba v kombinaciji z mofetilmikofenolatom (MMF), kortikosteroidi, in antagonistom receptorja IL-2, kot pri standardni negi, so primerjali v randomizirani, dvojno slepi, dvojno zakriti študiji, pri 543 bolnikih po novi presaditvi ledvice.
The efficacy and safety of Envarsus and Prograf, both in combination with mycophenolate mofetil (MMF) or mycophenolate sodium (MPS) and corticosteroids, was compared in 324 stable kidney transplant recipients.
Učinkovitost in varnost zdravila Envarsus in zdravila Prograf, oba v kombinaciji z mofetilmikofenolatom (MMF) ali natrijevim mikofenolatom (MPS) in kortikosteroidi, so primerjali pri 324 stabilnih bolnikih po presaditvi ledvice.
The efficacy and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer who had received docetaxel and were using a LHRH analogue or had undergone orchiectomy were assessed in a randomised, placebo-controlled, multicentre phase 3 clinical trial.
Učinkovitost in varnost enzalutamida pri bolnikih z metastatskim, proti kastraciji odpornim rakom prostate, ki so prejemali docetaksel in so uporabljali analog LHRH ali so opravili orhidektomijo, so ocenili v randomiziranem, s placebom kontroliranem multicentričnem kliničnem preskušanju 3. faze.
The efficacy and safety of eslicarbazepine acetate has been demonstrated in four phase III double- blind placebo-controlled studies in 1,703 randomized adult patients with partial epilepsy refractory to treatment with one to three concomitant anti-epileptic medicinal products.
Učinkovitost in varnost eslikarbazepinacetata so pokazali v štirih dvojno slepih, s placebom nadzorovanih študijah III. faze pri 1.703 randomiziranih odraslih bolnikih s parcialno epilepsijo, ki se odziva na zdravljenje z enim do tremi antiepileptiki.
The efficacy and safety of fondaparinux have not been formally studied in patients with HIT type II.
Pri bolnikih s HIT tipa II niso formalno proučevali učinkovitosti in varnosti fondaparinuksa.
The efficacy and safety of Humira were assessed in five randomised, double-blind and well-controlled studies.
Učinkovitost in varnost zdravila Humira za zdravljenje revmatoidnega artritisa so ocenili v petih randomiziranih, dvojno slepih in dobro kontroliranih študijah.